Can We Afford the New Era of Lung Cancer Survival?

For 3 decades, the clinical narrative for limited-stage small cell lung cancer (LS-SCLC) was one of grim consistency. Patients diagnosed with this aggressive neuroendocrine malignancy—a disease historically and inextricably linked to the stigma of heavy smoking—faced a poor prognosis. The standard of care, a combination of radiation and chemotherapy, offered a median overall survival of just 12 to 18 months. For generations of patients, the medical community could offer little more than a "watch and wait" approach once the initial treatment ended.

Recently, that stagnation was disrupted by the results of the ADRIATIC trial (NCT03703297), which positioned the immunotherapy drug durvalumab (Imfinzi) as a potent treatment option.¹

Yet, as the initial euphoria of a clinical breakthrough settles, a new economic evaluation published in JCO Global Oncology has cast a long shadow over the drug’s arrival. While durvalumab offers a genuine survival advantage, its implementation in the United States is colliding with a harsh economic reality: at its current price, the cost of survival may be higher than the system is willing—or able—to pay.²

Here, study authors Gilberto Lopes, MD, chief of Medical Oncology, and Chinmay Jani, MD, chief fellow, Hematology Oncology, Sylvester Comprehensive Cancer Center, provide exclusive insight into the rationale and findings of their study.

Cost-Effectiveness of the ADRIATIC Regimen

The rationale of the evaluation was straightforward: ADRIATIC showed meaningful survival benefit for durvalumab as consolidation/maintenance after chemoradiotherapy in LS-SCLC, but the high cost of durvalumab in the United States makes it important to evaluate value and budget impact in a disciplined way. High prices can translate into financial toxicity, reduced adherence, and discontinuation—effects that disproportionately harm vulnerable populations.

We therefore built a partitioned survival cost-effectiveness model comparing durvalumab vs standard of care, using the usually accepted $150,000/quality-adjusted life years (QALY) willingness-to-pay benchmark.

ADRIATIC showed meaningful modeled gains with durvalumab (overall survival, 66.1 vs 57.8 months; progression-free survival, 40.2 vs 31.8 months), but with substantially higher total costs.

The cost of durvalumab was $163,722 vs $25,816 for placebo, with an incremental cost-effectiveness ratio (ICER) of $383,069/QALY in the overall cohort—more than double the accepted US threshold.

But the drug’s economic value is not a monolith. In patients with extrathoracic progress, the ICER was $151,137 (0.59 QALY gain), compared with $410,166 (0.21 QALY gain) and $294,840 (0.32 QALY gain) in patients with intrathoracic and central nervous system progression, respectively.

However, we would be very cautious about using that subgroup finding to “prioritize” access or coverage decisions. While extrathoracic subgroup did show the lowest ICER and therefore looked most favorable economically in the model, it remains a subgroup, model-based inference, and it should be viewed as hypothesis-generating, not as a basis to restrict an FDA-approved, guideline-aligned therapy for eligible patients. Most importantly, this is a group defined after treatment so we would not be able to use this to select patients at the treatment decision point.

From an access standpoint, the priority should be the opposite: make the approved option reliably available for the indicated population, while using analyses like this to inform pricing and payment solutions—not to create new clinical gatekeeping.

The policy question becomes how to sustain access to an approved, life-extending therapy while minimizing financial harm. That frames the conversation around pricing and payment design rather than restricting patient access.

We estimate that to reach an ICER under $150,000/QALY, total durvalumab-arm costs would need to drop to <$79,816, corresponding to an average monthly cost of about $1,207 (vs ~$2476 modeled).

Key limitations of the study include that there was no post-progression therapy data to model downstream treatment costs/patterns. ADRIATIC did not include direct quality of life outcomes, so utilities were borrowed from prior SCLC sources. The baseline imaging/surveillance costs were assumed. Long-term survival is extrapolated with a 10-year horizon. Finally, the ICER should be interpreted as a structured estimate, not an immutable truth.

These findings should be used to reduce friction, not to erect barriers. Durvalumab is an FDA-approved therapy in LS-SCLC after chemoradiation, with demonstrated survival benefit; the goal should be reliable coverage and patient access while exploring value-based approaches that address affordability. Additionally, Medicare drug price negotiation reforms under the Inflation Reduction Act may affect part B drugs in coming years, and addressing affordability is important to avoid widening disparities.

Practically, the next step for the field would be to test whether any clinical or biological factors consistently predict larger durable benefit from consolidation immunotherapy.

This study reinforces a pattern we all recognize: US cancer drug prices are markedly higher than in other regions, and high prices can translate into financial toxicity that is not evenly distributed. The discussion explicitly links rising oncology costs and cost-sharing to financial burden, with disproportionate impact in vulnerable groups (including non-Hispanic Black patients and those with lower income and education), and downstream effects like worse quality of life, reduced adherence, and discontinuation.

The equity-forward stance is: protect access to the approved therapy while pushing for mechanisms—pricing reform, coverage policy, patient protections—that prevent cost from becoming a clinical contraindication. Coverage decisions should align with the approved indication and evidence base. If we want patients to benefit from evidence-based advances like durvalumab in LS-SCLC, we need policy and pricing approaches that protect access and reduce financial harm, rather than letting cost become a barrier.

REFERENCES

1. Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13. PMID: 39268857.

2. Jani C, Manoharan A, Han S, et al. Cost-effectiveness analysis of durvalumab in limited-stage small cell lung cancer in the United States. JCO Glob Oncol 11, e2500225(2025). doi:10.1200/GO-25-00225